Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2025-12-24 @ 9:45 PM
NCT ID:
NCT06979232
Eligibility Criteria:
Inclusion Criteria:
* 1\. Male or female aged 45 to 85
* 2\. Patients undergoing colonoscopy for colorectal cancer screening, positive fecal immunochemical test (FIT) results, gastrointestinal symptoms, or follow-up examination after colorectal polyp treatment
* 3\. Capable of providing informed consent and agreeing to participate
* 4\. Able and willing to follow all research processes
Exclusion Criteria:
* 1\. Participated in other clinical trials, signed informed consent form, and in the follow-up period of other clinical trials;
* 2\. Participated in clinical trials of drugs and is in the discontinuation period of experimental or control drugs;
* 3\. Have had drug or alcohol abuse or psychological disorders in the past five years.
* 4\. Pregnant or lactating patients;
* 5\. Known to have polyposis syndrome;
* 6\. Patients with gastrointestinal bleeding;
* 7\. Previous history of inflammatory bowel disease, colorectal cancer, or colorectal surgery;
* 8.Patients with contraindications to tissue biopsy;
* 9\. History of allergies to the ingredients in intestinal cleansers;
* 10\. Individuals with conditions such as intestinal obstruction or perforation, toxic megacolon, heart failure (grade III or IV), severe cardiovascular disease, severe liver failure, or renal insufficiency, among others.
* 11\. Researchers believe that patients are not suitable to participate in the trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
45 Years
Maximum Age:
85 Years
Study:
NCT06979232
Study Brief:
Protocol Section:
NCT06979232